Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs
Key Highlights
- ➤Femasys partners with SandsRx Pharmacy supporting FemaSeed portfolio launch to OB/GYNs
- ➤Partnership provides specialized pharmacy support, coordinated medication access and preferred pricing
- ➤FemaSeed Complete combines intratubal insemination with FemSperm for in-office fertility treatment
- ➤FemBloc advances toward U.S. FDA approval through ongoing FINALE pivotal trial
- ➤SandsRx offers fertility medications, insurance verification, financial assistance and coordinated delivery
Expert Statements
Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys
“FemaSeed is creating a new opportunity for OB/GYNs to provide first-line fertility treatment in their own practices, bringing care historically performed primarily by infertility specialists into a familiar setting.”
Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys
“FemaSeed places sperm directly where conception occurs, and managing ovulation and treatment timing is essential to supporting pregnancy outcomes.”
Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys
“Partnerships with specialty pharmacies such as SandsRx bring valuable medication expertise, education and coordination to practices introducing this treatment.”
Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys
“These resources help support successful integration of FemaSeed and our broader fertility portfolio into OB/GYN care.”
Mike Sands, Co-Founder and Chief Executive Officer of SandsRx Pharmacy
“We are excited to expand our fertility pharmacy support to OB/GYN practices through Femasys’ FemaSeed treatment solution.”
Mike Sands, Co-Founder and Chief Executive Officer of SandsRx Pharmacy
“We have supported the fertility community through reproductive centers, and this partnership allows us to reach patients earlier in their fertility journey through their OB/GYN.”
Mike Sands, Co-Founder and Chief Executive Officer of SandsRx Pharmacy
“By providing medication expertise, education and personalized support, we can help these practices integrate FemaSeed and guide patients through treatment with greater confidence.”
ATLANTA, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today an agreement with SandsRx Pharmacy, marking the first in a planned network of specialty pharmacy partnerships supporting the launch of FemaSeed and Femasys’ comprehensive fertility portfolio to OB/GYN practices. The partnership complements a portfolio spanning diagnostics for women and men, sperm preparation and in-office fertility treatment by providing specialized pharmacy support, coordinated medication access and preferred pricing. For patients undergoing FemaSeed treatment, fertility medications may be prescribed to support ovulation and improve the likelihood of pregnancy.
“FemaSeed is creating a new opportunity for OB/GYNs to provide first-line fertility treatment in their own practices, bringing care historically performed primarily by infertility specialists into a familiar setting,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys. “FemaSeed places sperm directly where conception occurs, and managing ovulation and treatment timing is essential to supporting pregnancy outcomes. Partnerships with specialty pharmacies such as SandsRx bring valuable medication expertise, education and coordination to practices introducing this treatment. These resources help support successful integration of FemaSeed and our broader fertility portfolio into OB/GYN care.”
Get started
Create a free account to read the full story.